S80 additional pre-HCT treatments with the goal of reducing the disease burden and “erasing” MRD. The hope is that, by doing so, post-HCT outcomes would be improved. While conceptually intuitive, there are so far no well-controlled prospective data to support this approach. In fact, there are concerns MRD-directed interventions before allogeneic HCT could worsen post-HCT outcomes (e.g., because toxicities encountered with such treatments could jeopardize the safety of allografting and increase non-relapse mortality) or render a patient ineligible for HCT altogether. Thus, additional pre-HCT therapies MRD-directed therapies to improve the best response prior to allogeneic HCT require careful study.
RkJQdWJsaXNoZXIy MTk3NTQxMg==